Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

× No keyword cloud information.

180 in total

1. An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.

Authors: Jonathan J Cho; Joshua M Stewart; Theodore T Drashansky; Maigan A Brusko; Ashley N Zuniga; Kyle J Lorentsen; Benjamin G Keselowsky; Dorina Avram
Journal: Biomaterials Date: 2017-07-24 Impact factor: 12.479

2. VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.

Authors: Blythe C Dillingham; Susan M Knoblach; Gina M Many; Brennan T Harmon; Amanda M Mullen; Christopher R Heier; Luca Bello; John M McCall; Eric P Hoffman; Edward M Connor; Kanneboyina Nagaraju; Erica K M Reeves; Jesse M Damsker
Journal: Cell Mol Neurobiol Date: 2014-11-13 Impact factor: 5.046

Review 3. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors: Reinhard Hohlfeld; Hartmut Wekerle
Journal: Proc Natl Acad Sci U S A Date: 2004-08-11 Impact factor: 11.205

Review 4. Is multiple sclerosis a disease that requires frequent beta interferon dosing?

Authors: Luca Durelli
Journal: J Neurol Date: 2004-09 Impact factor: 4.849

Review 5. What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors: Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal: J Neurol Date: 2004-09 Impact factor: 4.849

Review 6. Disease-modifying therapy in MS: a critical review of the literature. Part II: Assessing efficacy and dose-response.

Authors: Douglas S Goodin
Journal: J Neurol Date: 2004-09 Impact factor: 4.849

7. A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy.

Authors: Pietro Annovazzi; Valentina Tomassini; Benedetta Bodini; Laura Boffa; Massimiliano Calabrese; Eleonora Cocco; Cinzia Cordioli; Giovanna De Luca; Giovanni Frisullo; Antonio Gallo; Simona Malucchi; Damiano Paolicelli; Ilaria Pesci; Marta Radaelli; Paolo Ragonese; Luca Roccatagliata; Carla Tortorella; Marco Vercellino; Valentina Zipoli; Claudio Gasperini; Mariaemma Rodegher; Claudio Solaro
Journal: Neurol Sci Date: 2012-03-11 Impact factor: 3.307

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.